Food and Drug Administration

INMD DEADLINE NOTICE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages InMode Ltd. Investors with Losses in Excess of $100k to Secure Counsel Before Important April 15 Deadline in Securities Class Action - INMD

Retrieved on: 
星期三, 四月 3, 2024
Titan, Plaintiff, Food and Drug Administration, Class, Advertising, FDA, Court, Food

WHAT TO DO NEXT: To join the InMode class action, go to https://rosenlegal.com/submit-form/?case_id=22575 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the InMode class action, go to https://rosenlegal.com/submit-form/?case_id=22575 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages InMode Ltd. Investors with Losses in Excess of $100k to Secure Counsel Before Important Deadline in Securities Class Action - INMD

Retrieved on: 
星期一, 四月 1, 2024
Titan, Plaintiff, Food and Drug Administration, Class, Advertising, FDA, Court, Food

WHAT TO DO NEXT: To join the InMode class action, go to https://rosenlegal.com/submit-form/?case_id=22575 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the InMode class action, go to https://rosenlegal.com/submit-form/?case_id=22575 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Encourages InMode Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INMD

Retrieved on: 
星期日, 三月 17, 2024
Titan, Plaintiff, Food and Drug Administration, Class, Advertising, FDA, Court, Food

WHAT TO DO NEXT: To join the InMode class action, go to https://rosenlegal.com/submit-form/?case_id=22575 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the InMode class action, go to https://rosenlegal.com/submit-form/?case_id=22575 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

ROSEN, A LONGSTANDING LAW FIRM, Encourages InMode Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INMD

Retrieved on: 
星期六, 三月 16, 2024
Titan, Plaintiff, Food and Drug Administration, Class, Advertising, FDA, Court, Food

WHAT TO DO NEXT: To join the InMode class action, go to https://rosenlegal.com/submit-form/?case_id=22575 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the InMode class action, go to https://rosenlegal.com/submit-form/?case_id=22575 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma

Retrieved on: 
星期二, 四月 9, 2024
Disease, Osteosarcoma, Patient, Orphan, Food and Drug Administration, Cancer, Therapy, FDA, Food, Pharmaceutical industry

LSTA1 recently received Rare Pediatric Disease Designation for osteosarcoma, as announced by the Company on March 21, 2024.

Key Points: 
  • LSTA1 recently received Rare Pediatric Disease Designation for osteosarcoma, as announced by the Company on March 21, 2024.
  • “We are thrilled to have received another favorable regulatory designation from the FDA.
  • “Osteosarcoma, while rare, is a type of bone cancer that is often associated with high morbidity, early metastasis, rapid progression, and poor prognosis.
  • In addition to the financial benefits, it also may potentially shorten clinical development due to closer collaboration with the FDA.

Supernus Provides Regulatory Update for SPN-830

Retrieved on: 
星期一, 四月 8, 2024
Symantec Endpoint Protection, PD, Central nervous system, Patient, CNS, Food and Drug Administration, CRL, NDA, FDA, Food

ROCKVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced a regulatory update for SPN-830.

Key Points: 
  • ROCKVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced a regulatory update for SPN-830.
  • The FDA has issued a Complete Response Letter (CRL) in response to the Company’s New Drug Application (NDA) for SPN-830.
  • The CRL mentions two areas that require additional review by the FDA or additional information to be provided to the FDA.
  • We will work with the FDA to address the CRL and to successfully resubmit our SPN-830 NDA,” said Jack Khattar, President & CEO of Supernus.

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies 

Retrieved on: 
星期一, 四月 8, 2024
Principal, Malignancy, Risk, Patient, Food and Drug Administration, City, CRS, NHL, Mutagenesis, Therapy, Hematology, Bone marrow, B-cell lymphoma, APOLLO, Neurotoxicity, DLBCL, Cytokine release syndrome, Lymphoma, Press release

HOUSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today reported that Geoffrey Shouse, D.O., Ph.D., the Principal Investigator at City of Hope National Medical Center in Duarte, CA, was invited to present his clinical experience from the APOLLO study at the 11th Global Summit on Hematologic Malignancies in Whistler, BC, Canada (April 2-7, 2024). Dr. Shouse provided an overview on the clinical observations obtained at City of Hope on Saturday, April 6, 2024.

Key Points: 
  • Dr. Shouse provided an overview on the clinical observations obtained at City of Hope on Saturday, April 6, 2024.
  • During the presentation, Dr. Shouse showed that this study participant remains in CR nine months following initial treatment with MT-601.
  • This APOLLO participant had diffuse large B cell lymphoma (DLBCL) and failed four prior lines of therapy, including anti-CD19 CAR T cell therapy.
  • Dr. Shouse’s presentation included data from two additional study participants that have been treated at City of Hope.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against InMode, Innodata, Fox Factory, and X and Encourages Investors to Contact the Firm

Retrieved on: 
星期一, 四月 8, 2024
Research, Class Action, Growth, Palo Alto Networks, Federation, Defendant, Food and Drug Administration, Dermatology, News, AI, Nature, Silicon, Complaint, P.C, Goldengate, Research and development, Fox Factory, Confidentiality, Injury, Wolfpack, Marketing, Dentist, FDA

InMode is a global provider of aesthetic medical devices and technology, including devices purporting to offer body sculpting and other rejuvenation technologies.

Key Points: 
  • InMode is a global provider of aesthetic medical devices and technology, including devices purporting to offer body sculpting and other rejuvenation technologies.
  • Specifically, Defendants repeatedly touted the demand for InMode’s devices and told investors that those devices were never sold at a discount.
  • The complaint further alleges that when these misleading statements and omissions about Fox Factory’s business reached the market, investors were harmed significantly.
  • For more information on the Palo Alto Networks class action go to: https://bespc.com/cases/PANW

INVESTOR DEADLINE NEXT WEEK: Robbins Geller Rudman & Dowd LLP Announces that InMode Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - INMD

Retrieved on: 
星期一, 四月 8, 2024
SAN, Food and Drug Administration, News, Complaint, Pension fund, Food, FDA, Tobacco

), the InMode class action lawsuit charges InMode as well as certain of InMode’s top executives with violations of the Securities Exchange Act of 1934.

Key Points: 
  • ), the InMode class action lawsuit charges InMode as well as certain of InMode’s top executives with violations of the Securities Exchange Act of 1934.
  • Lead plaintiff motions for the InMode class action lawsuit must be filed with the court no later than April 15, 2024.
  • A lead plaintiff acts on behalf of all other class members in directing the InMode class action lawsuit.
  • An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the InMode class action lawsuit.

ROSEN, A LONGSTANDING LAW FIRM, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BLUE

Retrieved on: 
星期日, 四月 7, 2024
Titan, Patient, Class, Food and Drug Administration, Advertising, Bluebird, FDA, Court, Bluebird bio, Tobacco

WHAT TO DO NEXT: To join the bluebird class action, go to https://rosenlegal.com/submit-form/?case_id=23717 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the bluebird class action, go to https://rosenlegal.com/submit-form/?case_id=23717 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.